Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $240.00.

Several equities analysts recently commented on the stock. Deutsche Bank AG reaffirmed a “buy” rating and set a $255.00 price objective on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. TheStreet cut shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. Zacks Investment Research cut shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research note on Thursday, July 13th. They set an “outperform” rating and a $250.00 price objective for the company. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, July 14th.

Shares of Bio-Rad Laboratories (BIO) opened at 225.80 on Tuesday. Bio-Rad Laboratories has a one year low of $154.89 and a one year high of $242.79. The company has a market cap of $6.69 billion, a P/E ratio of 446.25 and a beta of 0.93. The stock’s 50 day moving average is $220.74 and its 200-day moving average is $217.89.

COPYRIGHT VIOLATION NOTICE: This article was published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/26/bio-rad-laboratories-inc-bio-given-consensus-rating-of-buy-by-analysts.html.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now directly owns 2,060 shares in the company, valued at $444,774.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 28.29% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. USA Financial Portformulas Corp bought a new stake in Bio-Rad Laboratories during the second quarter valued at approximately $782,000. Dynamic Technology Lab Private Ltd lifted its position in Bio-Rad Laboratories by 20.2% during the second quarter. Dynamic Technology Lab Private Ltd now owns 1,618 shares of the medical research company’s stock valued at $366,000 after purchasing an additional 272 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Bio-Rad Laboratories by 1.6% during the second quarter. Ameritas Investment Partners Inc. now owns 6,229 shares of the medical research company’s stock valued at $1,410,000 after purchasing an additional 100 shares during the last quarter. Martin & Co. Inc. TN lifted its position in Bio-Rad Laboratories by 0.6% during the second quarter. Martin & Co. Inc. TN now owns 6,825 shares of the medical research company’s stock valued at $1,545,000 after purchasing an additional 40 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its position in Bio-Rad Laboratories by 1.2% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,364 shares of the medical research company’s stock valued at $1,440,000 after purchasing an additional 78 shares during the last quarter. Institutional investors and hedge funds own 62.84% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.